PRRT – FDA Approves Lutathera®, What’s Next?
The FDA approval of Lutathera®, a peptide receptor radionuclide therapy (PRRT), on January 26, 2018 signals a new era in treatment options for the neuroendocrine cancer community. It has also raised a host of questions including:
- What exactly is
FDA Approves LUTATHERA® for Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors…READ MORE
News about Neuroendocrine Cancer Expert Physicians
Three appointments and a newly established one-year neuroendocrine tumor (NET) fellowship herald an exciting new year for several NET specialists.
Edward M. Wolin, MD, Co-Medical Director of the Carcinoid Cancer Foundation, has…READ MORE
NET Community Bicycle Raffle Recipients
In conjunction with Worldwide NET Cancer Awareness Day, November 10, the Carcinoid Cancer Foundation and Advanced Accelerator Applications are very excited to announce recipients of the recent Bicycle Giveaway Raffle.
Stefano Buono, CEO of Advanced…READ MORE
Free Kids’ Bicycles for the NET Cancer Community
Do you know a child in the NET cancer community – a child diagnosed with NET cancer or a child living in a family touched by NET disease – who would like to win a bicycle? The Carcinoid Cancer Foundation and Advanced Accelerator Applications are partnering…READ MORE
Gallium 68 PET/CT Scanning for Neuroendocrine Tumors — Information and Locations
The US Food and Drug Administration’s (FDA) June 1, 2016 approval of the Gallium-68 PET/CT DOTATATE scan using NETSPOT® heralded a new age of nuclear imaging for neuroendocrine tumors in the United States.PLEASE SCROLL DOWN FOR A STATE-BY STATE LIST… READ MORE
Carcinoid Syndrome Impact Survey Results to Be Presented During September 21 Webcast
Members of the carcinoid and neuroendocrine tumor community are invited to be the first to hear the results of the Carcinoid Syndrome Impact Survey that was conducted this summer. A Webcast about the survey results will be presented on Wednesday, September…READ MORE
October Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community
Join fellow carcinoid and neuroendocrine tumor (NET) patients and three medical experts for Luncheon with the Experts in New York City on Sunday, October 16, 2016. This special program was initiated and is sponsored by the Big Apple NETs support group,…READ MORE
Show Your Stripes by Contributing to Carcinoid and NET Research
Don’t miss this opportunity to Show Your Stripes by participating in the first ever Project Zebra: Real-World Patient Journey Research for Carcinoid and Neuroendocrine Tumors in the United States.
The Carcinoid Cancer Foundation…READ MORE
Neuroendocrine Tumor Patients and Clinical Trials — Seeking Volunteers for Interviews
A pharmaceutical partner has commissioned a research company to try to understand how clinical trials can be carried out in a way that better suits carcinoid/neuroendocrine tumor patients, their families, and the physicians who treat them. The research…READ MORE